Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Enlyte
Article
FDA Approves Combination NSAID/Opioid Seglentis
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
Enlyte
Article
FDA Approves Combination NSAID/Opioid Seglentis
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
PDF
Article
Specialty Services Are a Big Deal
When adjusters have to jump through hoops to make referrals, they lose precious time.
Mitchell
Virtual Event
Navigating Michigan’s No-Fault Auto Fee Schedule Four Months In
On-Demand
On July 2, 2021, Michigan’s new auto fee schedule went into effect for services rendered on or after that date.
Enlyte
News Release
Enlyte Family of Companies Publish Inaugural Report Offering Trends and Predictions for Property & Casualty (P&C) and Collision Repair Industries
SAN DIEGO—October 19, 2021—Enlyte, the new parent brand unifying Mitchell, Genex and Coventry, today released its inaugural report
Enlyte
News Release
Mitchell, Genex and Coventry Unite Under a Single, New Brand: Meet Enlyte
SAN DIEGO, CA—October 13, 2021—Mitchell, Genex and Coventry formally announced today the creation of their new parent brand, Enlyt